- Home
- SKWD vs AKRO Comparison
SKWD vs AKRO Comparison
Compare SKWD & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKWD
- AKRO
- Stock Information
- Founded
- SKWD 2007
- AKRO 2017
- Country
- SKWD United States
- AKRO United States
- Employees
- SKWD N/A
- AKRO N/A
- Industry
- SKWD Property-Casualty Insurers
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- SKWD Finance
- AKRO Health Care
- Exchange
- SKWD Nasdaq
- AKRO Nasdaq
- Market Cap
- SKWD 2.0B
- AKRO 1.8B
- IPO Year
- SKWD 2023
- AKRO 2019
- Fundamental
- Price
- SKWD $48.65
- AKRO $51.84
- Analyst Decision
- SKWD Buy
- AKRO Strong Buy
- Analyst Count
- SKWD 10
- AKRO 9
- Target Price
- SKWD $53.00
- AKRO $75.86
- AVG Volume (30 Days)
- SKWD 397.3K
- AKRO 2.2M
- Earning Date
- SKWD 02-25-2025
- AKRO 03-03-2025
- Dividend Yield
- SKWD N/A
- AKRO N/A
- EPS Growth
- SKWD 54.99
- AKRO N/A
- EPS
- SKWD 3.27
- AKRO N/A
- Revenue
- SKWD $1,092,093,000.00
- AKRO N/A
- Revenue This Year
- SKWD N/A
- AKRO N/A
- Revenue Next Year
- SKWD $12.02
- AKRO N/A
- P/E Ratio
- SKWD $14.88
- AKRO N/A
- Revenue Growth
- SKWD 32.05
- AKRO N/A
- 52 Week Low
- SKWD $33.27
- AKRO $17.86
- 52 Week High
- SKWD $55.62
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- SKWD 54.69
- AKRO 65.39
- Support Level
- SKWD $47.94
- AKRO $48.70
- Resistance Level
- SKWD $49.72
- AKRO $51.40
- Average True Range (ATR)
- SKWD 1.83
- AKRO 2.29
- MACD
- SKWD 0.28
- AKRO -0.90
- Stochastic Oscillator
- SKWD 67.78
- AKRO 35.50
About SKWD Skyward Specialty Insurance Group Inc.
Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.